Individualized Systemic Treatment of Lung Cancer

Individualized Systemic Treatment of Lung Cancer

The systemic treatment of lung cancer has revolutionized. New targeted treatment options have driven us to consider more specific subpopulations of lung cancer. For example , epidermal growth factor receptor (EGFR) inhibitors emerged as more effective in EGFR mutant patients. Crizotinib arose as a potent alternative in patients with ALK translocation. Histopathological subtypes and other predic...

Systemic treatment of non-small-cell lung cancer.

Lung cancer is in Poland the most common malignancy. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung tumors. In the multidisciplinary treatment of non-small cell lung cancer patients the role of chemotherapy and, most recently, molecular targeted therapy is increasing. In 2005 we published recommendations for systemic treatment of non-small cell lung cancer and mes...

Systemic treatment of non-small cell lung cancer brain metastases

In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): gefitinib or erlotinib, was an improvement in treatment of advanced NSCLC patients. EGFR mutations are prese...

Milestones in the systemic treatment of lung cancer

Several milestones in the systemic treatment of lung cancer have been reached. Combination chemotherapy of small cell lung cancer was the first of these milestones. The establishment of palliative chemotherapy in patients with advanced non-small cell lung cancer and of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer was another important milestone. Targeted...

Individualized Treatment of Early Breast Cancer